The new ADCs are rapidly changing the paradigm of treatment of HER2-positive advanced breast cancer patients and expanding the population that can benefit from them even in patients previously considered HER2-negative that have been defined as HER2-low.The results demonstrating the level of PFS achieved even in heavily pretreated populations indicate that these agents will improve survival. Here, ERBB2 is linked to breast carcinoma.